KEY INVESTIGATOR. If during the Research Period Xx. Xxxxxx Xxxxx's association with Rigel, in the capacity as chief scientific officer or a similar role ends for any reason and the Parties are unable to agree on a successor acceptable to Pfizer, in its sole and unfettered discretion, within one hundred eighty (180) days of his dissociation, Pfizer may terminate this Agreement pursuant to Section 8.3.1.
Appears in 5 contracts
Samples: Collaborative Research and License Agreement, Collaborative Research and License Agreement (Rigel Pharmaceuticals Inc), Collaborative Research and License Agreement (Rigel Pharmaceuticals Inc)